Sygnis Pharma, Systasy deal

Systasy acquired patents covering Sygnis' Split-TEV Double Switch technology. The IP is part of a broader IP family covering double switch technology, which qualitatively and quantitatively detects interactions of two proteins. The technology is based on the tobacco etch virus (TEV) protease, which Sygnis said has no targets in the human proteome and therefore does not cause any damage to mammalian cells. The protease can be used in its entirety (Full-TEV) or in a split version (Split-TEV) to detect protein-protein interactions in a "highly sensitive manner." Sygnis, which is retaining full rights to Full-TEV, said it is in "advanced negotiations" with potential partners to out-license Full-TEV for use in screening platforms and tests for the analysis of protein-protein interactions. ...